Literature DB >> 2397185

Serum interleukin-2 levels in a patient with focal segmental glomerulosclerosis. Relationship to clinical course and cyclosporin A therapy.

S C Jordan1, U Querfeld, M Toyoda, J Prehn.   

Abstract

We describe a patient with steroid-resistant focal segmental glomerulosclerosis (FSGS) whose serum interleukin-2 (IL-2) levels were markedly elevated in association with disease activity. With cyclosporin A (CsA) treatment, the patient entered remission and serum IL-2 fell to undetectable levels. After cessation of CsA, the patient relapsed and the serum IL-2 levels were elevated again. Reinstitution of CsA therapy was followed by a partial remission and disappearance of detectable serum IL-2 levels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2397185     DOI: 10.1007/bf00858831

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  7 in total

1.  Cyclosporine A induced remission of relapsing nephrotic syndrome in children.

Authors:  A T Tejani; K Butt; H Trachtman; M Suthanthiran; C J Rosenthal; M R Khawar
Journal:  Kidney Int       Date:  1988-03       Impact factor: 10.612

2.  Remission of idiopathic nephrotic syndrome after treatment with cyclosporin A.

Authors:  A Meyrier; P Simon; G Perret; M C Condamin-Meyrier
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-22

3.  Identification of the lymphokine soluble immune response suppressor in urine of nephrotic children.

Authors:  H W Schnaper; T M Aune
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

4.  Therapy of focal segmental glomerulosclerosis with cyclosporine A.

Authors:  F B Waldo; E C Kohaut
Journal:  Pediatr Nephrol       Date:  1987-04       Impact factor: 3.714

5.  Cyclosporin in the treatment of idiopathic nephrotic syndrome in children.

Authors:  P Niaudet; R Habib; M J Tete; N Hinglais; M Broyer
Journal:  Pediatr Nephrol       Date:  1987-10       Impact factor: 3.714

6.  Cyclosporine-induced remission of relapsing nephrotic syndrome in children.

Authors:  A Tejani; K Butt; H Trachtman; M Suthanthiran; C J Rosenthal; M R Khawar
Journal:  J Pediatr       Date:  1987-12       Impact factor: 4.406

7.  Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man.

Authors:  S C Textor; K Margolin; D Blayney; J Carlson; J Doroshow
Journal:  Am J Med       Date:  1987-12       Impact factor: 4.965

  7 in total
  1 in total

Review 1.  FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.

Authors:  A W Thomson; P B Carroll; J McCauley; J Woo; K Abu-Elmagd; T E Starzl; D H Van Thiel
Journal:  Springer Semin Immunopathol       Date:  1993
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.